Publication | Closed Access

Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma

Lymphoid NeoplasiaHistone Deacetylase InhibitorMedicinePeripheral T-cell LymphomaMalignant Blood DisorderImmunologyPathologySynergistic Antitumor EffectAnti-cancer AgentAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCancer Research